Study: Biohit's GastroPanel reduced waiting lists
Summary
- Biohit announced a peer-reviewed study confirming the GastroPanel test's effectiveness in reducing endoscopy waiting lists and aiding gastric cancer risk classification, supporting its sales and marketing efforts.
- The study, conducted in Chile, showed an 87% reduction in endoscopy waiting lists, highlighting the test's ability to prioritize patients and reduce unnecessary procedures.
- Scientific evidence from the study enhances the test's credibility, aiding its integration into national treatment protocols and screening programs, with potential expansion in neighboring countries.
- Despite the study's positive implications, current revenue and EBIT estimates for 2026 remain unchanged, but it supports Biohit's long-term growth prospects and strategic goals.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 04/22/2026 at 07:00 am EEST
Biohit announced on Tuesday a new peer-reviewed study whose results supported the company's value proposition regarding the benefits of the GastroPanel test in gastric cancer risk classification and reducing waiting lists. The study results provide the company with important scientific evidence to support sales and marketing, which is crucial, particularly in new markets and public healthcare projects. The study is based on a project conducted in Chile, which has already led to the adoption of GastroPanel as part of the national cancer prevention strategy.
Significant decrease in endoscopy waiting list lengths
According to a study published in Helicobacter, the use of the GastroPanel test in assessing the need for treatment (triage) led to a significant 87% decrease in endoscopy waiting lists in Molina, Chile. The test combines biomarker-based diagnostics with risk algorithms, enabling safe prioritization of patients requiring endoscopy and reducing unnecessary procedures. Similar evidence has also been obtained previously from the domestic Kappa study, which found that up to 90% of endoscopies could be avoided based on the GastroPanel result.
Scientific evidence supports long-term growth
Biohit has previously communicated the commercial progress of the Chilean pilot program. The publication of peer-reviewed research, along with previous studies, helps to further build the test's recognition and credibility. In our view, independent scientific evidence is essential for the test to be more widely incorporated into national treatment protocols and screening programs. Concrete evidence of this has already been seen in Chile, and similar programs also have potential in Chile's neighboring countries.
We currently expect revenue of 17.0 MEUR for 2026 (+8.0% vs. 2025) and adjusted EBIT of 2.6 MEUR (15.4% of revenue). Although the study now published does not change our near-term estimates, it supports the company's growth prospects. It also improves the preconditions for achieving the strategic annual growth of 15–20% in the longer term, provided that new market openings progress.
Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures12.02
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 15.7 | 17.0 | 18.7 |
| growth-% | 9.6 % | 8.0 % | 10.1 % |
| EBIT (adj.) | 2.9 | 2.6 | 3.0 |
| EBIT-% (adj.) | 18.5 % | 15.4 % | 16.0 % |
| EPS (adj.) | 0.18 | 0.15 | 0.17 |
| Dividend | 0.00 | 0.04 | 0.05 |
| Dividend % | 1.7 % | 1.9 % | |
| P/E (adj.) | 20.8 | 18.0 | 15.7 |
| EV/EBITDA | 15.9 | 10.3 | 6.6 |
Forum discussions
